Early endarterectomy carries a lower procedural risk than early stenting in patients with symptomatic stenosis of the internal carotid artery – results from four randomized controlled trials

Barbara Rantner MD, PhD;1 Barbara Kollerits PhD;2 Gary S Roubin, MD;3 Peter A Ringleb, MD;4 Olaf Jansen, MD;5 George Howard, PhD;6 Jeroen Hendrikse, MD;7 Alison Halliday, MD;8 John Gregson;9 Hans-Henning Eckstein, MD;10 David Calvet, MD;11 Richard Bulbulia, MD;12 Leo H Bonati, MD;13,14 Jean-Pierre Becquemin, MD;15 Ale Algra, MD;16,17 Martin M Brown, MD;14* Jean-Louis Mas, MD;18* Thomas G Brott, MD;19* Gustav Fraedrich, MD;1*#

On behalf of the Carotid Stenosis Trialists’ Collaboration.

*Contributed equally

1. Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria
2. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria
3. Cardiovascular Associates of the Southeast, Birmingham, AL
4. Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany
5. Clinic for Radiology and Neuroradiology, UKSH Campus Kiel, Kiel, Germany
6. Department of Biostatistics, UAB School of Public Health, Birmingham, AL
7. Department of Radiology, University Medical Centre Utrecht, Utrecht, the Netherlands
8. Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom
9. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
10. Department of Vascular and Endovascular Surgery/Vascular Centre, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany

11. Department of Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France

12. Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Oxford University, Oxford, United Kingdom

13. Department of Neurology and Stroke Centre, University Hospital Basel, Basel, Switzerland

14. Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, United Kingdom

15. University of Paris, XII, Vascular Surgery, Hôpital Henri Mondor, Créteil, France

16. Department of Neurology and Neurosurgery, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands

17. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands

18. Department of Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France

19. Department of Neurology, Mayo Clinic, Jacksonville, FL

# Corresponding author:

Gustav Fraedrich MD
Department of Vascular Surgery
Medical University Innsbruck
Anichstrasse 35
6020 Innsbruck
Email: gustav.fraedrich@i-med.ac.at
Tel: +43-50504-22587

Fax: +43-50504-2559
Abstract

Background and Purpose
Patients undergoing carotid endarterectomy (CEA) for symptomatic stenosis of the internal carotid artery (ICA) benefit from early intervention. Heterogeneous data are available on the influence of timing of carotid artery stenting (CAS) on procedural risk.

Methods
We investigated the association between timing of treatment (0-7 days and >7 days after the qualifying neurological event) and the 30-day risk of stroke or death after CAS or CEA in a pooled analysis of individual patient data from four randomized trials by the Carotid Stenosis Trialists’ Collaboration (CSTC). Analyses were done per protocol. To obtain combined estimates, logistic mixed models were applied.

Results
Among a total of 4138 patients a minority received their allocated treatment within seven days after symptom onset (14% CAS versus 11% CEA). Among patients treated within one week of symptoms, those treated by CAS had a higher risk of stroke or death compared with those treated with CEA: 8.3% vs 1.3%, risk ratio (RR) 6.7, 95% CI 2.1-21.9 (adjusted for age at treatment, sex and type of qualifying event). For interventions after one week, CAS was also more hazardous than CEA: 7.1% vs 3.6%, adjusted RR 2.0, 95% CI 1.5-2.7 (p value for interaction with time interval 0.06).

Conclusions
In randomized trials comparing stenting with carotid endarterectomy for symptomatic carotid artery stenosis, CAS was associated with a substantially higher periprocedural risk during the first seven days after the onset of symptoms. Early surgery is safer than stenting for preventing future stroke.
Clinical Trial Registration

Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00190398.

Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN 57874028

Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN 25337470

Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00004732.
Background

Carotid artery stenting (CAS) has evolved as an alternative treatment for carotid artery disease. Over the last 20 years, CAS has striven to prove its feasibility and efficacy in stroke prevention when compared with that of carotid endarterectomy (CEA) for patients with symptomatic internal carotid artery (ICA) stenosis. Because of the high risk of early stroke recurrence after plaque rupture, it is now accepted that intervention offers the greatest benefit when performed soon after the onset of neurological symptoms\textsuperscript{1, 2}. The somewhat greater perioperative risk of rapid CEA is offset by a much lower risk of stroke recurrence\textsuperscript{3}.

Timing of treatment could also influence the results of carotid artery stenting. Unlike early surgery, CAS seems to be a higher risk procedure when performed soon after symptoms.

The 2012 analysis based on individual patient-level data from three randomized trials comparing CAS and CEA reported by the Carotid Stenosis Trialists’ Collaboration (CSTC) suggested that timing of intervention influenced the occurrence of outcomes. CAS between day 0 and 7 was associated with the highest number of procedural complications when compared with patients treated between 8 and 14 days, or thereafter. In contrast, surgery during each of these time intervals was safer\textsuperscript{4}.

In this updated analysis, we added data from individual patients with symptomatic carotid stenosis from the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). This provided the largest group yet studied of patients with symptomatic carotid stenosis randomized between CEA and CAS, and enabled us to investigate associations between periprocedural outcome and timing of treatment for both techniques.
Methods

Four randomized clinical trials with blinded adjudicated outcomes were included; EVA-3S (NCT 00190398), SPACE (ISRCTN 57874028), ICSS (ISRCTN 25337470) and CREST (NCT 00004732). In the first 3 of these trials, patients with symptomatic moderate to severe carotid stenosis (≥50% stenosis measured according to NASCET criteria\(^5\)), deemed suitable for both procedures, were randomly allocated to CAS or CEA\(^6\)\(^-\)\(^8\). Our pooled analysis of individual patient data was prospectively agreed at the design stage of the three European trials\(^9\). Data on symptomatic patients from CREST were added in 2015. CREST included patients with transient ischaemic attack (TIA), amaurosis fugax and minor non-disabling ischaemic stroke. To be eligible for CREST, patients had to have a carotid artery stenosis of at least 50% on invasive angiography, 70% or more on ultrasound, or 70% or more on computed tomographic or magnetic resonance angiography if the stenosis was 50-69% on ultrasound\(^{10}\). The primary outcome for the present analysis was the combination of any stroke or death occurring within 30 days after treatment. Secondary outcome events were any stroke and fatal or disabling stroke happening within the same time period. The analysis was done per-protocol: patients were only included in the analysis if the randomly allocated treatment was the first initiated revascularization procedure and if either the date of the qualifying event (the last ischaemic event ipsilateral to the carotid artery being randomized in the trial), or the interval between the qualifying event and treatment was known. Patients with missing data on delay between qualifying event and treatment were excluded from the analysis. In three studies (EVA-3S, ICSS and CREST), the date of the qualifying event was entered at baseline. In the SPACE trial the date of the qualifying event was not prospectively assessed at study entry, however, the date of the qualifying event was retrospectively retrieved whenever possible for this pooled analysis. If the exact date was unknown, patients were included if
information was available whether treatment had taken place within seven days of the qualifying event or thereafter.
Statistical Analysis

To obtain a combined estimate (risk ratio (RR) with 95% confidence intervals (CI)), logistic mixed models were applied with the source study as random variable using a log-link. The first model was unadjusted whereas the second model accounted for age at treatment, sex, and type of qualifying event (retinal ischaemia, TIA, or stroke). Age at treatment was log-transformed based on the natural logarithm (ln) in the mixed model analysis. In contrast to our previous analysis, just two timing groups were created, because results of patients treated between 8-14 days or thereafter were similar (Supplementary Table I), irrespective of the treatment technique. Therefore the primary analysis compared patients treated within 7 days of neurological symptoms or thereafter. Secondly, an interaction between timing of treatment and treatment effect (CAS versus CEA) was tested by integrating a multiplicative interaction term in the logistic mixed model analyses. A p value of <0.10 for interaction terms was considered statistically significant, for all other statistical analyses a p-value of <0.05 was considered to indicate statistical significance.

Results

Baseline characteristics

The pooled data set for all four trials included 4754 patients with symptomatic ICA stenosis. 2361 patients were randomized to CEA (49.7%) and 2393 patients to CAS. For both treatment groups a number of patients were excluded from data analysis due to missing information about their most recent neurological event, or the treatment date (n=290 patients in the CEA group and n=274 in the CAS group). Another 52 patients (26 in each treatment group) were excluded because they did not receive the initially allocated treatment. Figure 1 gives detailed information about included and excluded patients by source trial. In total, 4138 patients (n=2045 in the CEA and 2093 in the CAS group) remained for per protocol analysis. Table 1 summarizes the baseline characteristics of both treatment groups. The median delay between
the most recent neurological event and treatment was 26 days [interquartile range: 11-61] for CAS and 29 days [interquartile range: 13-67] for CEA. Among 4138 patients, a small but relevant group underwent CAS and CEA within a week of their symptoms (14% in CAS vs. 11% in CEA). Treatment groups did not differ for neurological parameters and comorbidities. Baseline characteristics were additionally provided for the two timing groups (Table 2).

Supplementary table II compares patients included and excluded from the current analysis due to available or missing timing information. There were some minor and most probably random differences in baseline characteristics of these two groups.

**Overall outcome in the study population for both treatment groups (CAS vs. CEA)**

The risk of any stroke or death within 30 days after treatment was higher for the CAS compared with the CEA group for the entire study population: 7.3% vs. 3.3%, crude RR 2.29, 95% CI 1.71-3.08. This association remained significant when the model was additionally adjusted for age at treatment, sex and type of qualifying event (RR 1.92, 95% CI 1.50-2.47).

**Outcome in both treatment groups by timing of treatment (0-7 days and > 7 days)**

In the early period after the onset of neurological symptoms (0 to 7 days), CAS had the highest number and proportion of periprocedural strokes and deaths (n=24/287, 8.4%), compared with CEA (n=3/226, 1.3%). Patients in the CAS group had a higher risk of any stroke or death in the crude (RR 6.51, 95% CI 2.00-21.21) and adjusted models (RR 6.74, 95% CI 2.07-21.92) (Figure 2 and Table 3).

Compared with those treated within 7 days, patients treated after 7 days had fewer strokes and deaths in the CAS group (n=129/1806, 7.1%), while the risk of stroke and death in the CEA group slightly increased (n=65/1819, 3.6%). The risk ratio for CAS compared with CEA was still higher in this later treatment group: RR_{crude} 2.00, 95% CI 1.49-2.67 (Table 3); RR_{adjusted} 2.00, 95% CI 1.50-2.68 (Figure 2). Results were almost identical for the outcome analysis of
any stroke: $RR_{crude}$ for CAS in the early treatment group 6.27, 95% CI 1.92-20.44; $RR_{crude}$ for CAS after 7 days 1.98, 95% CI 1.47-2.67 (Table 3). Adjustment did not importantly change results (Figure 2). The analysis of fatal or disabling stroke outcome at 30 days also showed that the crude risk ratio was higher for CAS than the CEA group within 7 days (RR 8.29, 95% CI 1.07-64.28) and after 7 days (RR 1.77, 95% CI 1.10-2.85) (Table 3). Results were virtually unchanged after adjustment (Figure 2).

Interaction between time and relative risks of CAS versus CEA

The test for interaction between timing of treatment and treatment effect (CAS versus CEA) revealed a p value of 0.07 in the crude and 0.06 in the adjusted model for the outcome any stroke or death. Comparable results were seen for the outcome any stroke at 30 days (p=0.07 for both models). There was no statistically significant interaction seen for fatal or disabling stroke (p=0.17; Figure 2).

Discussion

Carotid artery stenting is not as safe as carotid endarterectomy in the treatment of patients with symptomatic stenosis of the internal carotid artery irrespective of the timing of treatment. The difference in safety between CAS and CEA is particularly potent in patients treated within 7 days of symptom onset.

There has been a heated debate as to whether early surgery in symptomatic patients is safe and meaningful. However, it is now widely accepted that early plaque removal effectively reduces stroke risk. Although early surgery may be associated with a slightly higher risk of perioperative complications, it still offers the best chance of a symptomatic patient avoiding future stroke\(^3,11\). Recent literature on the risk of stroke recurrence after initial plaque rupture provides somehow controversial results. Most authors suggest that the risk of early recurrent stroke from symptomatic ICA stenosis remains high\(^12-14\). In a very recently published series of
377 patients with symptomatic ICA stenosis stroke recurrence rate reached 2.7% within the first day, 5.3% within three days and 18.8% within 90 days after the qualifying event\textsuperscript{14}. Only one retrospective Swedish study reported a lower overall number of second events in 397 patients with symptomatic stenosis of the ICA (for recurrent stroke 2.0%, 95% CI 0.6-3.4 by day 2, 2.4%, 95% CI 2.0-5.9 by day 7 and 7.5%, 95% CI 4.4-10.6 by day 30)\textsuperscript{15}. In accordance with that results from a medical intervention study revealed that the number of neurological events was significantly reduced with the application of best medical treatment after symptom onset. The intake of aspirin, clopidogrel and a statin could relevantly decrease the number of recurrent neurological events in a series of 188 patients\textsuperscript{16}.

Data from the SWEDVASC registry were analyzed to investigate the time dependence of CEA outcome among more than 2500 symptomatic patients. The authors found that rapid surgery (between 0-2 days) was associated with a significantly higher frequency of perioperative complications (any stroke or death) when compared with patients treated between 3 and 7 days, 8 and 14 days and thereafter (11.5% vs. 3.6% vs. 4.0% vs. 5.4%, p<0.001, respectively)\textsuperscript{17}. Only a small number of SWEDVASC patients were treated in the very early period (5.7%), which might limit the generalizability of these registry data. In contrast, their slight increase in perioperative complications was not replicated in two single center studies \textsuperscript{18,19}. Both studies reported comparable perioperative complication rates for the same four surgical timing groups. A recent analysis of more than 56,000 patients with symptomatic ICA stenosis from the German nationwide statutory quality assurance registry also revealed no outcome difference between patients treated early by CEA (within 48 hours) and thereafter (any stroke or death 3.0% for CEA between 0-2 days vs. 2.5% between 3-7 days vs. 2.6% between 8-14 days vs. 2.3% for CEA thereafter)\textsuperscript{20}. In addition, data from the National Vascular Registry from the UK illustrated comparable outcomes for the four timing groups among more than 23,000 symptomatic patients\textsuperscript{21}. Complementary to this register data which only contained CEA patients, results from the National (Nationwide) Inpatient Sample
(NIS) were published. In this analysis authors investigated the influence of ultra-early revascularizations (within 48 hours) on the outcome of CAS and CEA in more than 70,000 symptomatic patients. The comparison between CAS and CEA when performed within 48 hours after the onset of symptoms showed that CAS was associated with significantly more periprocedural complications, regardless of whether patients had a cerebral infarction on admission or not (OR 3.45, 95% CI 3.13-3.80, p<0.01 for CAS patients with infarct on admission compared with CEA under same conditions; OR 2.53, 95% CI 2.40-2.66, p<0.001 for CAS patients without infarct on admission compared with CEA again under same conditions)\textsuperscript{22}. The authors did not find any outcome differences after later treatment for both CEA and CAS. Recently the influence of timing on the outcome of CAS and CEA was also analyzed in the CREST data. The authors used three timing groups (CAS or CEA <15 days, 15-60 days and thereafter) and did not see any time-dependence for periprocedural outcome for both treatment techniques (HR for stroke or death in the CAS group comparing 15-60d days to <15 days 1.15, 95% CI 0.48-2.75 and 1.12, 95% CI 0.53-2.40 comparing >60days to <15 days, both p=0.93). For the CEA group comparing 15-60d days to <15 days the HR was 0.74, 95% CI 0.22-2.49 and 0.91, 95% CI 0.25-3.33, respectively, comparing >60days to <15 days, both p=0.89)\textsuperscript{23}. Differences in the findings between the CREST trial alone and the pooled CSTC data of all four randomized trials might be due to different time strata, making results more difficult to compare.

In the present report we found that early CEA (in the period of 0-7 days after the onset of symptoms) had the lowest absolute risk for periprocedural complications for all three outcomes, while surgical risks in the later period were somewhat higher (e.g., any stroke or death 1.3% for 0-7 days vs. 3.6% after 7 days). In contrast, early CAS carried the highest periprocedural stroke or death risk, decreasing slightly in the later period (8.4% vs. 7.1%). This suggests that the recently symptomatic ICA plaque with a ruptured plaque surface needs some time for stabilization to allow safer catheter passage in CAS\textsuperscript{24, 25}. The clinical decision
to perform early revascularization of symptomatic carotid stenosis is likely influenced by characteristics of the patient and the symptomatic event. For example, we saw in both treatment groups that the percentage of patients with a hemispheric stroke prior to inclusion was about 10% higher in patients treated late than in patients treated early (Table 2). It is possible that clinically more stable patients were predominantly selected for early treatment.

In another analysis of the NIS, the authors focused on patients with symptomatic ICA stenosis and recent cerebral infarction. Analyses were done in four timing groups: CEA or CAS within 48 hours after the onset of symptoms, between 48 hours and 4 days, between 5 and 7 days and between 8 and 14 days. Amongst the 27839 patients with recent cerebral infarction, patients treated between five and seven days after symptoms had the lowest probability of periprocedural complications (OR 0.64, 95% CI 0.56-0.74, p<0.001) and mortality (OR 0.63, 95% CI 0.45-0.89, p<0.001), irrespective of the treatment technique. Without having details about cerebral lesions we found in the CSTC population that CEA was most beneficial when performed between 0 and 7 days, whereas CAS was most harmful during the first week after the onset of symptoms. Due to small numbers of patients who were treated early after the onset of symptoms and relatively small numbers of periprocedural complications in both treatment groups we could not build further time groups to determine an ideal time point for CAS and CEA amongst our study population.

**Limitations of our analysis**

Timing of treatment has to date never been a randomization criterion in larger trials. All information on the influence of timing of treatment is derived from post hoc analysis of randomized controlled trials comparing two treatment techniques (best medical treatment vs. CEA or CEA vs. CAS). Therefore, detailed information on patient selection and disease severity is lacking. This significantly limits the value of timing analysis so far. A randomized trial on timing of treatment would be mandatory in the near future.
Recent ischaemic infarction on neuroimaging is reported to be a relevant risk factor for periprocedural complications after CAS as well as after CEA. Unfortunately, detailed findings from baseline CT or MRI were not available for the present analysis. The use of embolic protection devices (EPD) was mandatory in CREST, but not in the three remaining trials. We could therefore not deliver detailed outcome analysis of CAS under the use of EPD compared to CEA.

**Conclusion**

Carotid endarterectomy is very effective at preventing stroke. Early plaque removal can be performed without relevantly increasing perioperative complications. In contrast, carotid artery stenting during the early period after plaque rupture is associated with an increased risk of periprocedural complications. We could clearly demonstrate in this randomized and large population of symptomatic patients that risk differences between CAS and CEA were greatest in the early days after the index symptom. Early CEA was associated with the lowest risk of periprocedural complications. We therefore conclude that early carotid endarterectomy compared with early carotid artery stenting after an initial neurological event offers the highest stroke prevention benefit for the patient at risk.
Authors’ contributions

BR wrote the first draft of the report and was supervised by GF. BK, BR and GF designed the statistical analysis plan and BK undertook the statistical analyses. JLM, PAR, LHB and GH extracted patients’ data from contributing trials. All the authors listed in the writing committee made substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data; and also contributed to drafting the report or revising it critically for important intellectual content. Last but 3 author, last but 2 author, last but 1 author and last author contributed equally to the report. GF had the final responsibility for the analyses and the content of the report.

Disclosures: None.

Sources of funding:

L.H. Bonati was supported by grants from the Swiss National Science Foundation (PBBSB-116873), the University of Basel, Switzerland, and The Stroke Association. M.M. Brown’s Chair in Stroke Medicine at University College London is supported by the Reta Lila Weston Trust for Medical Research. Part of this work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centers funding scheme. A. Halliday’s research is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Center. G. Howard is funded by the National Institute of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS).

Detailed information about the Carotid Stenosis Trialists’ Collaboration and Acknowledgments are added in the supplementary material.
Reference List


### Table 1 Baseline data of the combined trial population according to treatment group (CAS and CEA)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>CEA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at treatment (years)</strong></td>
<td>69.4±9.2</td>
<td>69.5±9.3</td>
</tr>
<tr>
<td></td>
<td>[63,70,76]</td>
<td>[63,70,77]</td>
</tr>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>1449 (69)</td>
<td>1442 (71)</td>
</tr>
<tr>
<td><strong>History of diabetes, n (%)</strong></td>
<td>519 (25)</td>
<td>507 (25)</td>
</tr>
<tr>
<td><strong>History of hypertension, n (%)</strong></td>
<td>1570 (75)</td>
<td>1552 (76)</td>
</tr>
<tr>
<td><strong>History of hypercholesterolemia, n (%)</strong></td>
<td>1142 (55)</td>
<td>1172 (57)</td>
</tr>
<tr>
<td><strong>Any smoking history (current/past), n (%)</strong></td>
<td>1317 (63)</td>
<td>1310 (64)</td>
</tr>
<tr>
<td><strong>History of coronary heart disease, n (%)</strong></td>
<td>572 (27)</td>
<td>576 (28)</td>
</tr>
<tr>
<td><strong>History of peripheral artery disease, n (%)</strong></td>
<td>173 (8)</td>
<td>161 (8)</td>
</tr>
<tr>
<td><strong>Degree of ipsilateral carotid stenosis, n (%)</strong></td>
<td>Moderate (50-69%)</td>
<td>366 (17)</td>
</tr>
<tr>
<td></td>
<td>Severe (70-99%)</td>
<td>1727 (83)</td>
</tr>
<tr>
<td><strong>Contralateral severe carotid stenosis (≥70%) or occlusion, n (%)</strong></td>
<td>208 (10)</td>
<td>204 (10)</td>
</tr>
<tr>
<td><strong>Type of most recent ipsilateral ischaemic event before randomization, n (%)</strong></td>
<td>TIA</td>
<td>774 (37)</td>
</tr>
<tr>
<td></td>
<td>Retinal ischaemia</td>
<td>363 (17)</td>
</tr>
<tr>
<td></td>
<td>Hemispheric stroke</td>
<td>942 (45)</td>
</tr>
<tr>
<td><strong>modified Rankin Score (mRS) at baseline</strong></td>
<td>mRS=0, n (%)</td>
<td>1033 (49)</td>
</tr>
<tr>
<td></td>
<td>mRS=1, n (%)</td>
<td>564 (27)</td>
</tr>
<tr>
<td></td>
<td>mRS=2, n (%)</td>
<td>334 (16)</td>
</tr>
<tr>
<td></td>
<td>mRS=3, n (%)</td>
<td>114 (5)</td>
</tr>
<tr>
<td></td>
<td>mRS=4, n (%)</td>
<td>26 (1)</td>
</tr>
<tr>
<td></td>
<td>mRS=5, n (%)</td>
<td>1 (0.05)</td>
</tr>
<tr>
<td><strong>History of stroke before most recent event, n (%)</strong></td>
<td>371 (18)</td>
<td>365 (18)</td>
</tr>
<tr>
<td><strong>Days elapsed between most recent ipsilateral ischaemic event and treatment</strong></td>
<td>45.5±50.6</td>
<td>49.8±59.1</td>
</tr>
<tr>
<td></td>
<td>[11,26,61]</td>
<td>[13,29,67]</td>
</tr>
<tr>
<td><strong>Treatment within 7 days of most recent event</strong></td>
<td>287 (14)</td>
<td>226 (11)</td>
</tr>
</tbody>
</table>

Mean ± standard deviation (SD) and [25th, 50th, 75th percentile] in case of non-normal distribution; interquartile range (IQR): 25th - 75th percentile] or number (%)

CAS: carotid artery stenting, CEA: carotid endarterectomy; TIA: transient ischemic attack

a Data collected in EVA-3S, ICSS and CREST only.
b Data collected in EVA-3S and ICSS only.
c Degree of stenosis measured by NASCET method or equivalent non-invasive method.
d Protocols of contributing trials excluded patients with disabling strokes.
The date of the most recent ipsilateral ischaemic event before randomization was not collected in the SPACE trial initially, but for the meta-analysis these dates (or if the exact date was unknown, whether or not randomization and treatment took place within 7 days of the qualifying event), were retrieved where available.
| Table 2: Baseline data of the combined trial population according to timing of treatment (0-7 days and > 7 days) in the two treatment groups (CAS and CEA) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | **0-7 days**    | **>7 days**     |                 |                 |
|                 | CAS             | CEA             | CAS             | CEA             |
|                 | n=287           | n=226           | n=1806          | n=1819          |
| Age at randomization (years) | 68.3±9.0 [62,69,75] | 69.2±8.9 [63,70,76] | 69.6±9.2 [63,70,77] | 69.6±9.4 [63,70,77] |
| Male, n (%)     | 198 (69)        | 157 (69)        | 1251 (69)       | 1285 (71)       |
| History of diabetes, n (%) | 82 (29)        | 55 (24)         | 437 (24)        | 452 (25)        |
| History of hypertension, n (%) | 220 (77)       | 189 (84)        | 1350 (75)       | 1363 (75)       |
| History of hypercholesterolemia, n (%)\(^a\) | 164 (57)       | 123 (54)        | 978 (54)        | 1049 (58)       |
| Any smoking history (current/past), n (%) | 191 (67)       | 146 (65)        | 1126 (62)       | 1164 (64)       |
| History of coronary heart disease, n (%) | 89 (31)        | 77 (34)         | 483 (27)        | 499 (27)        |
| History of peripheral artery disease, n (%)\(^b\) | 12 (4)         | 11 (5)          | 161 (9)         | 150 (8)         |
| Degree of ipsilateral carotid stenosis, n (%)\(^c\) | Moderate (50-69%) | 54 (19)        | 38 (17)         | 312 (17)        | 331 (18)       |
|                 | Severe (70-99%) | 233 (81)        | 188 (83)        | 1494 (83)       | 1488 (82)      |
| Contralateral severe carotid stenosis (>70%) or occlusion, n (%)\(^c\) | 16 (5.6)       | 14 (6.2)        | 192 (11)        | 190 (10)        |
| Type of most recent ipsilateral ischaemic event before randomization, n (%) | TIA | 146 (51) | 112 (50) | 628 (35) | 649 (36) |
|                 | Retinal ischaemia | 37 (13) | 30 (13) | 326 (18) | 317 (17) |
|                 | Hemispheric stroke | 101 (35) | 83 (37) | 841 (47) | 840 (46) |
| modified Rankin Score (mRS) at baseline\(^d\) | mRS=0, n (%) | 138 (48) | 119 (53) | 895 (50) | 875 (48) |
|                 | mRS=1, n (%)    | 91 (32)      | 68 (30)         | 473 (26)        | 471 (26)       |
|                 | mRS=2, n (%)    | 38 (13)      | 32 (14)         | 296 (16)        | 310 (17)       |
Mean ± standard deviation (SD) and [25th, 50th, 75th percentile] in case of non-normal distribution; interquartile range (IQR): 25th - 75th percentile or number (%)

CAS: carotid artery stenting, CEA: carotid endarterectomy; TIA: transient ischaemic attack

\[ mRS=3, n (%) \]
\[
\begin{array}{cccc}
13 (5) & 4 (2) & 101 (6) & 120 (7) \\
4 (1) & 1 (0.4) & 22 (1) & 23 (1) \\
0 (0) & 0 (0) & 1 (0.06) & 3 (0.2) \\
43 (15) & 28 (12) & 328 (33) & 337 (33)
\end{array}
\]

\[ \text{History of stroke before most recent event, n (%)} \]

\[ mRS=4, n (%) \]

\[ mRS=5, n (%) \]

\[ \text{Data collected in EVA-3S, ICSS and CREST only.} \]

\[ \text{Data collected in EVA-3S and ICSS only.} \]

\[ \text{Degree of stenosis measured by NASCET method or equivalent non-invasive method.} \]

\[ \text{Modified Rankin Scores at baseline may reflect non-stroke impairments; protocols of contributing trials excluded patients with disabling strokes.} \]
Table 3: Logistic mixed models of two treatment groups (CAS vs. CEA) depending on timing of treatment (0-7 days and >7 days) on three different outcomes within 30 days after treatment (any stroke or death, any stroke and fatal or disabling stroke).

<table>
<thead>
<tr>
<th></th>
<th>CEA n event/ n total (%)</th>
<th>CAS n event/ n total (%)</th>
<th>Crude RR (95% CI) *</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any stroke or death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-7 days</td>
<td>3/226 (1.3)</td>
<td>24/287 (8.4)</td>
<td>6.51 (2.00-21.21)</td>
<td>0.002</td>
</tr>
<tr>
<td>&gt;7 days</td>
<td>65/1819 (3.6)</td>
<td>129/1806 (7.1)</td>
<td>2.00 (1.49-2.67)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Any stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-7 days</td>
<td>3/226 (1.3)</td>
<td>23/287 (8.0)</td>
<td>6.27 (1.92-20.44)</td>
<td>0.002</td>
</tr>
<tr>
<td>&gt;7 days</td>
<td>62/1819 (3.4)</td>
<td>122/1806 (6.8)</td>
<td>1.98 (1.47-2.67)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Fatal or disabling stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-7 days</td>
<td>1/226 (0.4)</td>
<td>9/287 (3.1)</td>
<td>8.29 (1.07-64.28)</td>
<td>0.04</td>
</tr>
<tr>
<td>&gt;7 days</td>
<td>26/1819 (1.4)</td>
<td>46/1806 (2.5)</td>
<td>1.77 (1.10-2.85)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

* CEA represents reference group.

CAS: carotid artery stenting, CEA: carotid endarterectomy, CI: confidence interval
Figure 1: Flow diagram of patients included in the meta analysis referring to source trial

PP_initiated=0 reflects patients who did not receive the primarily allocated treatment technique. Those patients were excluded for per protocol analysis

#1 2093 CAS patients: 260 (12.4%) EVA-3S, 381 (18.2%) SPACE, 828 (39.6%) ICSS, 624 (29.8%) CREST;

#2 2045 CEA patients: 257 (12.6%) EVA-3S, 365 (17.8%) SPACE, 819 (40.0%) ICSS, 604 (29.5%) CREST

PP: per protocol, CAS: carotid artery stenting, CEA: carotid endarterectomy

Figure 2: Forest plot illustrating the adjusted relative risk of two treatment groups (CAS vs. CEA) in two timing groups (0-7 days and >7 days) on three different outcomes within 30 days after treatment (any stroke or death, any stroke and fatal or disabling stroke). Model adjusted for age at treatment, sex, and type of qualifying event (retinal ischaemia, TIA, or stroke)